Response to Comments: MolDX: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease

This document is an administrative response to comments regarding the MolDX: Prolaris prostate cancer genomic assay for men with favorable intermediate risk disease and provides the LCD comment, notice, and finalization dates. The excerpt contains no clinical coverage criteria, limitations, documentation requirements, or frequency limits; consult LCD DL37142 (final 07/10/2017) for the full coverage policy. Manual review is required to extract actionable coverage rules from the referenced LCD.

"Policy text contains only the administrative timeline for the MolDX: Prolaris prostate cancer genomic assay (comment period 2017-02-16 to 2017-04-03; notice period 2017-05-25 to 2017-07-09; LCD fin..."

Sign up to see full coverage criteria, indications, and limitations.